Open an account

Vincerx Pharma

VINC · NASDAQ

$0.015+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.015

About VINC

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.

Employees
12
Headquarters
Palo Alto, California
Listed
Mar 10, 2020
Sector
Health Care
Industry
Biotechnology
Website
vincerx.com

VINC key statistics

Market cap
78.51K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
815
Volume
5
Open price
$0.015
High today
$0.015
Low today
$0.015
52 Week high
$0.045
52 Week low
$0.0002

Vincerx Pharma (VINC) at a glance

As of Oct 20, 2026, Vincerx Pharma (VINC) shares are priced at $0.015, giving the company a market cap of 78.51K and a price-to-earnings ratio of 0.00.

Volume so far is 5 shares, below the average of 815 shares a day.

Over the past year Vincerx Pharma has ranged from $0.0002 to $0.045, and now sits 33% of the way up that range.

Vincerx Pharma met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q4 FY24 it reported -$4.20 per share against an estimate of -$3.47.

VINC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 30.7% on average.

  1. Q1 FY23: reported -$13.60 per share against an estimate of -$10.61
  2. Q2 FY23: reported -$10.40 per share against an estimate of -$12.17
  3. Q3 FY23: reported -$9.20 per share against an estimate of -$9.32
  4. Q4 FY23: reported -$4.60 per share against an estimate of -$7.48
  5. Q1 FY24: reported -$11.60 per share against an estimate of -$4.79
  6. Q2 FY24: reported -$1.00 per share against an estimate of -$4.18
  7. Q3 FY24: reported -$3.40 per share against an estimate of -$4.42
  8. Q4 FY24: reported -$4.20 per share against an estimate of -$3.47

VINC news

  • Rishabh Mishra

    US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert

  • Avi Kapoor

    Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results

  • Avi Kapoor

    Nasdaq Gains Over 100 Points; Delta Air Lines Posts Upbeat Earnings

  • Rishabh Mishra

    US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert

  • Rishabh Mishra

    US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert

  • Press releasePRNewswire

    SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders

  • Press releaseBusiness Wire

    VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, VINC, OMIC on Behalf of Shareholders

Similar companies

Companies in the same industry as Vincerx Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.